The purpose of this clinical trial is to evaluate the efficacy and tolerability of Levetiracetam administered three times daily in patients with epilepsy. The primary objective is to investigate whether orally administered Levetiracetam three times daily dosing is superior in seizure-free days compared to standard twice-daily dosing in patients with epilepsy.

Key questions include:

• Does LEV improve seizure control, as measured by seizure-free days?
• What adverse events or safety concerns are observed with LEV treatment?

Participants will receive Levetiracetam administered three times daily during the treatment phase. The study will use a self-matched, pre-post design in which each participant serves as their own control. Baseline seizure activity and safety data will be collected prior to LEV initiation and compared with data obtained during the treatment period. Participants will attend scheduled clinic visits for efficacy and safety evaluations and will maintain a daily diary to record seizure frequency and any treatment-related events.

Inclusion Criteria:

• Aged 18 years or older.
• diagnosed with uncontrolled Epilepsy of any type (defined as one or more unprovoked seizures in the last 6 months)
• On Levetiracetam monotherapy
• Participants must have a documented history of Levetiracetam use for at least 12 months prior to enrollment.
• on Levetiracetam high dose (1.5 - 3 g daily)

Exclusion Criteria:

• Younger than Aged 18 years
• Received Levetiracetam intravenous within the last 24hr.
• Co-administered with other antiepileptic drugs
• Received other antiepileptic drugs in the last two weeks.
• Pregnant women.
• Renal impairment (Crcl < 30) or Acute kidney injury

confidentiality agreement